When a doctor requests treatment for a patient in an out-of-reach country, my job is to ensure medicine gets to that patient. Multiply this by 30,000 patients across 70+ countries,...
March 9th is a day of mourning and grief for The Max Foundation and for anyone who knows our story and loves the Organization. On March 9th 1991, 30 years...
In 2008, Osbaldo was diagnosed with chronic myeloid leukemia (CML) at the young age of 24. Osbaldo shares his journey accessing treatment.
Dr. Ong Tee Chuan, Hematologist at Hospital Ampang, Malaysia, break down what access to treatment means for the patients he treats.
Providing dignity and hope for patients and their families is both challenging and rewarding.
They’re patients, physicians, pharmacists, police officers, caregivers, and cancer care advocates stepping up to help vulnerable patients continue to have access to treatment throughout the global pandemic closures.
Bunthan Kahn was diagnosed with chronic myeloid leukemia (CML) in 2017. He’s a tour guide, a husband, a young father, and an avid learner. From traveling far to meet with specialized physicians, to seeking treatment in his country, his journey toward finding hope took perseverance.
For the 20th anniversary of World Cancer Day, we asked our global team members, physicians, patients, caregivers, and advocates to share what progress in cancer care means to them. Progress...
One of the things I observed at Maputo Central Hospital was the level of comfort and trust between the physician and the patient. It is remarkable because until today the doctors had no effective treatment to give. And yet the patients came back, time after time, for regular check-ups, never losing hope.
In 2011, Carmen developed a fever that lasted for weeks and began losing weight rapidly. After multiple doctors, tests, and misdiagnoses, she finally discovered she had chronic myeloid leukemia. Carmen feared her life was over. She even went so far as to sew her own funeral dress. Eventually, Carmen learned that her cancer could be managed through oral treatment, but the costs were prohibitive. Luckily her physician was a Max Foundation partner. She was able to enroll in our access program for imatinib at no cost, and all seemed well for a few years—until, that is, she stopped responding to her initial treatment.
All of us at The Max Foundation are wholly committed to maximizing every opportunity to collaborate and build new partnerships on behalf of the patients we serve in low resource settings. We are excited to move onward to a new chapter with innovative opportunities to expand our impact. We hope you will see a place for yourself to join us in this effort to close the cancer divide!
A “cold-chain” product must remain within a specific temperature range at all times. On days- or weeks-long international shipments, it’s especially challenging (and expensive) to keep medicine at a constant temperature. Despite the inherent challenges, adding cold-chain capability is well worth the effort for the patients we support. By doing so, The Max Foundation will be able to better meet the needs of patients who are unresponsive to tablet therapies.